Biohit Oyj

Board/Management Information • May 28, 2012

Disclosure 300178

Biohit Oyj - Changes board/management/auditors

Changes to Biohit Oyj’s management

Biohit Oyj Changes to Biohit Oyj´s management 28 May 2012 9:30 a.m. Jussi Kolunen (born 1969), M.Sc. (Econ.), has been appointed CFO at Biohit Oyj as of 28 May 2012. He has previously been responsible for Bridgestone Finland Oy's financial administration (2005-present), and held the position of Business Controller at Xerox Oy (2003-2005) and Fujitsu Invia (1999-2003). Biohit's former CFO, Ulla Savelainen, will retire after the transition phase. Biohit's Management Team now includes the following members and functions: Semi Korpela, CEO Jussi Kolunen, Finance and HR Anu Mickels, Sales and Marketing Panu Hendolin, Research and Product Development Tapani Tiusanen, Operations and ICT Lea Paloheimo, Development and Quality Irene Hernberg, Communications Semi Korpela, M.Sc. (Econ.) CEO, Biohit Group Tel.: +358 9 773 861 Mobile: +358 40 573 7701 semi.korpela@biohit.fi BIOHIT Healthcare Innovating for Health Distribution: NASDAQ OMX Helsinki Oyj Central Storage Facility (www.oam.fi) Press www.biohithealthcare.com About Biohit Biohit Oyj is a globally operating Finnish biotechnology company that was established in 1988. The company's mission is to improve human health and quality of life. Biohit specialises in products and systems that promote the diagnosis and prevention of diseases of the gastrointestinal tract. Innovations and patents The company follows a goal-directed and long-term innovation and patenting strategy with scientific communities. New technology based on research results and innovations is used to produce new solutions for medical science and research institutions in order to promote research and people's wellbeing. Diagnostics The diagnostics business comprises products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood sample-based GastroPanel examinations for the diagnosis of stomach diseases and their associated risks; quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy; and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. Biohit's Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic stomach. The Biohit Group The Group employs about 35 people. Biohit is headquartered in Helsinki and the company has a subsidiary in the UK. Biohit's products are also sold globally through numerous distributors. Biohit is headquartered in Helsinki and the company has a subsidiary in the UK. Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. It is traded under the code BIOBV (www.biohit.com/investors).